Your browser doesn't support javascript.
loading
Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model.
Mavaddat, Nasim; Ficorella, Lorenzo; Carver, Tim; Lee, Andrew; Cunningham, Alex P; Lush, Michael; Dennis, Joe; Tischkowitz, Marc; Downes, Kate; Hu, Donglei; Hahnen, Eric; Schmutzler, Rita K; Stockley, Tracy L; Downs, Gregory S; Zhang, Tong; Chiarelli, Anna M; Bojesen, Stig E; Liu, Cong; Chung, Wendy K; Pardo, Monica; Feliubadaló, Lidia; Balmaña, Judith; Simard, Jacques; Antoniou, Antonis C; Easton, Douglas F.
Afiliação
  • Mavaddat N; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Ficorella L; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Carver T; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Lee A; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Cunningham AP; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Lush M; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Tischkowitz M; Department of Medical Genetics and National Institute for Health Research, Cambridge Biomedical Research Centre, The University of Cambridge, Cambridge, United Kingdom.
  • Downes K; Cambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Hu D; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.
  • Hahnen E; Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Schmutzler RK; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Stockley TL; Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Downs GS; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Zhang T; Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Chiarelli AM; Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Bojesen SE; Department of Laboratory Medicine and Pathobiology, The University of Toronto, Ontario, Canada.
  • Liu C; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, Canada.
  • Chung WK; Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Pardo M; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, Canada.
  • Feliubadaló L; Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Balmaña J; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
  • Simard J; Ontario Health, Cancer Care Ontario, Toronto, Ontario, Canada.
  • Antoniou AC; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Easton DF; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
Cancer Epidemiol Biomarkers Prev ; 32(3): 422-427, 2023 03 06.
Article em En | MEDLINE | ID: mdl-36649146
ABSTRACT

BACKGROUND:

The multifactorial risk prediction model BOADICEA enables identification of women at higher or lower risk of developing breast cancer. BOADICEA models genetic susceptibility in terms of the effects of rare variants in breast cancer susceptibility genes and a polygenic component, decomposed into an unmeasured and a measured component - the polygenic risk score (PRS). The current version was developed using a 313 SNP PRS. Here, we evaluated approaches to incorporating this PRS and alternative PRS in BOADICEA.

METHODS:

The mean, SD, and proportion of the overall polygenic component explained by the PRS (α2) need to be estimated. $\alpha $ was estimated using logistic regression, where the age-specific log-OR is constrained to be a function of the age-dependent polygenic relative risk in BOADICEA; and using a retrospective likelihood (RL) approach that models, in addition, the unmeasured polygenic component.

RESULTS:

Parameters were computed for 11 PRS, including 6 variations of the 313 SNP PRS used in clinical trials and implementation studies. The logistic regression approach underestimates $\alpha $, as compared with the RL estimates. The RL $\alpha $ estimates were very close to those obtained by assuming proportionality to the OR per 1 SD, with the constant of proportionality estimated using the 313 SNP PRS. Small variations in the SNPs included in the PRS can lead to large differences in the mean.

CONCLUSIONS:

BOADICEA can be readily adapted to different PRS in a manner that maintains consistency of the model. IMPACT The methods described facilitate comprehensive breast cancer risk assessment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article